MAPT and Alzheimer disease: Importantly, for the differential diagnosis of AD it is unlikely that any of the hundreds of proposed AD CSF biomarker candidates will reach the diagnostic performance of the three core biomarkers Aβ, T-tau and P-tau, since these reflect the pathological hallmarks of the disease and have been verified in large prospective studies and meta-analyses [72].